

**Biota Holdings Limited**

ACN 006 479 081

10/585 Blackburn Road  
Notting Hill VIC 3168  
Australia**T** +61 3 9915 3700**F** +61 3 9915 3702**E** info@biota.com.au**W** www.biota.com.au*For Immediate Release*

Melbourne, Australia — 27 July 2011

**Royalties from Relenza for Q4 and F2011**

Biota Holdings Limited (ASX:BTA) today announced that it had received written notification from GlaxoSmithKline (GSK) that indicative royalties from Relenza were \$1.8m during the three months ended 30 June 2011. F2011 actual royalties are \$6.6m.

Indicative royalties and sales advised by GSK by quarter for the full financial year, are summarised below:

	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>Adjustment*</b>	<b>Total</b>
Indicative royalties \$m	2.1	1.2	1.0	1.8	0.5	6.6
Indicative sales \$m	29.6	17.9	14.1	18.0	-	79.6

\* Adjusts indicative royalties reported during the year to actual and includes exchange rate corrections where appropriate.

**About Biota**

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product Inavir<sup>®</sup>, is approved for marketing in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza<sup>™</sup> is a registered trademark of the GlaxoSmithKline group of companies.

Inavir<sup>®</sup> is registered to Daiichi Sankyo.

**Investor / Analyst Enquiries****Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

**Media Enquiries**

Nerida Mossop, Hinton &amp; Associates

T: +61 3 9600 1979 / M: +61 437 361 433

**US Enquiries**

Hershel Berry, Blueprint Life Science Group

M: +1 415 505 3749